ALKBH5 and lung carcinoma: These results indicate that the KRAS mutant promotes chemoresistance in lung cancer cells, a phenomenon correlated with the upregulation of ERK/JNK signaling as well as increased ALKBH5 phosphorylation and SUMOylation.